A new agent, gallium-68 dotatate (Netspot®), recently FDA-approved and available at Roswell Park, can be used as a PET tracer instead of the glucose to identify carcinoid tumors—even very small lesions—significantly better than any currently available imaging.
There are certain times of year when my cancer story makes me feel incredibly isolated. There’s the time surrounding April 14, the day I was diagnosed, July 29, the day I was deemed “in remission” and, the one I’ve experienced most recently, the month of October.
The 2015 Neuroendocrine Tumor (NET) Patient Regional Meeting is coming up on Saturday, Aug. 29. NET patients and caregivers are invited for an afternoon of networking, information sharing and support—all tailored to the unique needs of the NET patient community.